I have always thought the NEU strategy was (can’t remember what lead me to this) that Trofenitide would be sold as a stand alone drug, and that enough work would be done on NNZ-2591 to realize optimum value, with an ultimate sale of the drug in total.
Ill admit that things seem to have moved from there - to NEU possibly going the whole way alone / but the bottom line is that if a sale was to materialise for NEU I never thought that Trofenitide would be part of it.
So the RoW rights doesn’t impact this approach.
I have always thought the NEU strategy was (can’t remember what...
-
- There are more pages in this discussion • 622 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.22 |
Change
0.950(7.16%) |
Mkt cap ! $1.776B | |||
| Open | High | Low | Value | Volume |
| $13.80 | $14.35 | $13.53 | $4.447M | 319.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 564 | $14.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.22 | 366 | 11 |
View Market Depth
| Last trade - 11.23am 07/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |